Seizure syndrome in stroke and traumatic brain injury: Incidence and treatment outcomes in the intensive care unit

  • Received 30.06.2025
  • Revised 18.11.2025
  • Accepted 30.12.2025
  • Published 06.01.2026
  • 670 Views
  • Retrieved from Vol. 11, No. 2, 2025
  • Pages 14-25

Seizure syndrome is one of the most common and complex neurological complications in patients with acute brain injuries, particularly following stroke and traumatic brain injury. This complication significantly worsens clinical outcomes, increases the risk of mortality, and prolongs patients’ length of stay in the intensive care unit. This study aimed to determine the frequency of seizure syndrome in patients with stroke and traumatic brain injury, to analyse the main causes of its development, and to evaluate the efficacy and safety of antiepileptic therapy in order to improve treatment approaches and clinical outcomes. A comprehensive literature review was conducted using 50 relevant scientific publications from PubMed, Scopus, Web of Science and Google Scholar databases. The selection was carried out in accordance with PRISMA guidelines and included studies with clearly defined patient populations with stroke or traumatic brain injury, data on seizure frequency, antiepileptic drug use, and statistically analysed results published in peer reviewed journals. Published studies indicated that seizure syndrome occurs in approximately 15%- 30% of patients after stroke and in 20%-40% of individuals with traumatic brain injury. Early seizures (within the first seven days) are consistently reported in approximately 7% of patients after stroke and are associated with a poorer prognosis. The literature review identified multifactorial pathophysiological mechanisms, including primary structural brain tissue damage, secondary metabolic disorders, neuroinflammation, and an imbalance of neurotransmitter systems. Data from numerous studies demonstrated a high efficacy of modern antiepileptic therapy – particularly levetiracetam and lorazepam – estimated at 70%-85% with a favourable safety profile. The binding of levetiracetam to synaptic vesicle protein 2A is widely regarded as a key mechanism of seizure control, while lorazepam remains a first-line drug for the acute management of seizures due to its enhancement of GABAergic transmission

antiepileptic therapy; levetiracetam; lorazepam; neurological complications; neuroinflammation

https://doi.org/10.63341/ijmmr/2.2025.14
  1. Galovic M, Ferreira-Atuesta C, Abraira L, Döhler N, Sinka L, Brigo F, et al. Seizures and epilepsy after stroke: Epidemiology, biomarkers and management. Drugs Aging. 2021;38(4):285–99. DOI: 10.1007/s40266-021-00837-7
  2. Ferreira-Atuesta C, Döhler N, Erdélyi-Canavese B, Felbecker A, Siebel P, Scherrer N, et al. Seizures after ischemic stroke: A matched multicenter study. Ann Neurol. 2021;90(5):808–20. DOI: 10.1002/ana.26212
  3. Nandan A, Zhou YM, Demoe L, Waheed A, Jain P, Widjaja E. Incidence and risk factors of post-stroke seizures and epilepsy: Systematic review and meta-analysis. J Int Med Res. 2023;51(11):3000605231213231. DOI: 10.1177/03000605231213231
  4. Misra S, Kasner SE, Dawson J, Tanaka T, Zhao Y, Zaveri HP, et al. Outcomes in patients with poststroke seizures: A systematic review and meta-analysis. JAMA Neurol. 2023;80(11):1155–65. DOI: 10.1001/jamaneurol.2023.3240
  5. Wang Z, Xu H, Liu J, Lin R, He D, Yang Y, et al. An automatic deep-learning approach for the prediction of post-stroke epilepsy after an initial intracerebral hemorrhage based on non-contrast computed tomography imaging. Quant Imaging Med Surg. 2025;15(2):1175–89. DOI: 10.21037/qims-24-1345
  6. Scarpino M, Grippo A, Campagnini S, Hakiki B, Maiorelli A, Sodero A, et al. Stroke-related epilepsy in the rehabilitation setting: Insights from the inpatient post-stroke rehabilitation study – RIPS. Epilepsy Behav Rep. 2024;28:100713. DOI: 10.1016/j.ebr.2024.100713
  7. Peter-Derex L, Philippeau F, Garnier P, André-Obadia N, Boulogne S, Catenoix H, et al. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21(9):781–91. DOI: 10.1016/S1474-4422(22)00235-6
  8. Oder of Ministry of Health of Ukraine No. 276. On the Approval and Implementation of Medical and Technological Documents for the Standardization of Medical Care for Epilepsy [Internet]. 2014 April 17 [cited 2025 April 17]. Available from: https://zakon.rada.gov.ua/rada/show/v0276282-14#Text
  9. Frontera JA, Gilmore EJ, Johnson EL, Olson D, Rayi A, Tesoro E, et al. Guidelines for seizure prophylaxis in adults hospitalized with moderate-severe traumatic brain injury: A clinical practice guideline for health care professionals from the Neurocritical Care Society. Neurocrit Care. 2024;40:819–44. DOI: 10.1007/s12028-023-01907-x
  10. Frontera JA, Rayi A, Tesoro E, Gilmore EJ, Johnson EL, Olson D, et al. Guidelines for seizure prophylaxis in patients hospitalized with nontraumatic intracerebral hemorrhage: A clinical practice guideline for health care professionals from the Neurocritical Care Society. Neurocrit Care. 2025;42:1–21. DOI: 10.1007/s12028-024-02183-z
  11. Kälviäinen R. Guideline 00766: Treatment of prolonged seizure episodes and status epilepticus. Kyiv: Ministry of Health of Ukraine; 2017. 5 P.
  12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:71. DOI: 10.1136/bmj.n71
  13. Neri S, Gasparini S, Pascarella A, Santangelo D, Cianci V, Mammì A, et al. Epilepsy in cerebrovascular diseases: A narrative review. Curr Neuropharmacol. 2023;21(8):1634–45. DOI: 10.2174/1570159X20666220706113925
  14. Ma S, Fan X, Zhao X, Wang K, Wang H, Yang Y. Risk factors for early-onset seizures after stroke: A systematic review and meta-analysis of 18 observational studies. Brain Behav. 2021;11(6):e02142. DOI: 10.1002/brb3.2142
  15. Kauk O, Bondarenko Y, Kulyk D. Prognostic value of inflammatory biomarkers (CRP, IL-6, procalcitonin) in patients with ischemic stroke in intensive care. Psychiatry Neurol Med Psychol. 2025;13(29):344–56. DOI: 10.26565/2312-5675-2025-29-05
  16. Bondarenko Y, Kulyk D, Kauk O. Cognitive impairment after the hemorrhagic and ischemic stroke: Is it possible to minimize its development already in intensive care? Grail Sci. 2025;51:862–76. DOI: 10.36074/grail-of-science.18.04.2025.116
  17. Pease M, Gonzalez-Martinez J, Puccio A, Nwachuku E, Castellano JF, Okonkwo DO, et al. Risk factors and incidence of epilepsy after severe traumatic brain injury. Ann Neurol. 2022;92(4):663–9. DOI: 10.1002/ana.26443
  18. Sødal HF, Storvig G, Tverdal C, Robinson HS, Helseth E, Taubøll E. Early post-traumatic seizures in hospitalized patients with traumatic brain injury. Acta Neurol Scand. 2022;146(5):485–91. DOI: 10.1111/ane.13670
  19. Fordington S, Manford M. A review of seizures and epilepsy following traumatic brain injury. J Neurol. 2020;267(10):3105–11. DOI: 10.1007/s00415-020-09926-w
  20. Teneralli RE, Cepeda MS, Kern DM, Novak GP. Individuals who develop drug-resistant epilepsy within a year after initial diagnosis have higher burden of mental and physical diseases one-year prior to epilepsy diagnosis as compared to those whose seizures were controlled during the same interval. Epilepsy Behav. 2021;123:108243. DOI: 10.1016/j.yebeh.2021.108243
  21. Okada T, Suzuki H, Travis ZD, Zhang JH. The stroke-induced blood-brain barrier disruption: Current progress of inspection technique, mechanism, and therapeutic target. Curr Neuropharmacol. 2020;18(12):1187–212. DOI: 10.2174/1570159X18666200528143301
  22. Mankovskyi DS. Clinical and anamnestic predictors of postoperative hypoxic and ischemic brain lesions and algorithms for their assessment of neurological support of сardiac surgery patients. Bull Med Biol Res. 2021;3(3):42–8. DOI: 10.11603/bmbr.2706-6290.2021.3.12568
  23. Rosenow F, Weber J. S2k guidelines: Status epilepticus in adulthood: Guidelines of the German Society for Neurolog. Nervenarzt. 2021;92(10):1002–30. DOI: 10.1007/s00115-020-01036-2
  24. Misirocchi F, Quintard H, Kleinschmidt A, Schaller K, Pugin J, Seeck M, et al. ICU-electroencephalogram unit improves outcome in status epilepticus patients: A retrospective before-after study. Crit Care Med. 2024;52(11):545–56. DOI: 10.1097/CCM.0000000000006393
  25. Hakami T. Efficacy and tolerability of antiseizure drugs. Ther Adv Neurol Disord. 2021;14:17562864211037430. DOI: 10.1177/17562864211037430
  26. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Neurology. 2004;62(8):1252–60. DOI: 10.1212/01.wnl.0000123693.82339.fc
  27. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Neurology. 2018;91(2):74–81. DOI: 10.1212/WNL.0000000000005755
  28. Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363–74. DOI: 10.1016/S0140-6736(21)00247-6
  29. Bayat A, Fenger CD, Techlo TR, Højte AF, Nørgaard I, Hansen TF, et al. Impact of genetic testing on therapeutic decision-making in childhood-onset epilepsies – a study in a tertiary epilepsy center. Neurotherapeutics. 2022;19(4):1353–67. DOI: 10.1007/s13311-022-01264-1
  30. Castellotti B, Ragona F, Freri E, Messina G, Magri S, Previtali R, et al. Next-generation sequencing in pediatric-onset epilepsies: Analysis with target panels and personalized therapeutic approach. Epilepsia Open. 2024;9(5):1922–30. DOI: 10.1002/epi4.13039
  31. Balaji A, Mohanlal S, Pachat D, Babu SS, Kumar ES, Mamukoya N, et al. Genome-based therapeutics: Era of precision medicine in genetic epilepsies and epileptic encephalopathies. Ann Indian Acad Neurol. 2023;26(5):723–7. DOI: 10.4103/aian.aian_314_23
  32. Na JH, Lee H, Lee YM. Clinical efficacy and safety of the ketogenic diet in patients with genetic confirmation of drug-resistant epilepsy. Nutrients. 2025;17(6):979. DOI: 10.3390/nu17060979
  33. Sharma E, Pomianoski BW, Jabbar R, Ayesha A, Silva YP, Łajczak P, et al. Responsive neurostimulation for patients with refractory mesial temporal lobe epilepsy: A systematic review and meta-analysis. Epilepsy Behav Rep. 2025;30:100774. DOI: 10.1016/j.ebr.2025.100774
  34. Wu S, Nordli DR. Motor seizure semiology. Handb Clin Neurol. 2023;196:295–304. DOI: 10.1016/B978-0-323-98817-9.00014-4
  35. Stirling RE, Cook MJ, Grayden DB, Karoly PJ. Seizure forecasting and cyclic control of seizures. Epilepsia. 2020;62(1):2–14. DOI: 10.1111/epi.16541
  36. Xu MY. Poststroke seizure: Optimising its management. Stroke Vasc Neurol. 2019;4(1):48–56. DOI: 10.1136/svn-2018-000175
  37. Brondani R, Garcia de Almeida A, Abrahim Cherubini P, Mandelli Mota S, de Alencastro LC, Antunes ACM, et al. High risk of seizures and epilepsy after decompressive hemicraniectomy for malignant middle cerebral artery stroke. Cerebrovasc Dis Extra. 2017;7(1):51–61. DOI: 10.1159/000458730
  38. Mariajoseph FP, Muthusamy S, Amukotuwa S, Seneviratne U. Seizure-induced reversible MRI abnormalities in patients with single seizures: A systematic review. Epileptic Disord. 2023;23(4):552–62. DOI: 10.1684/epd.2021.1300
  39. Szűcs A, Rosdy B, Kelemen A, Horváth A, Halász P. Reflex seizure triggering: Learning about seizure producing systems. Seizure. 2019;69:25–30. DOI: 10.1016/j.seizure.2019.03.019
  40. Perucca E, Bialer M, White HS. New GABA-targeting therapies for the treatment of seizures and epilepsy: I. Role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system. CNS Drugs. 2023;37(9):755–79. DOI: 10.1007/s40263-023-01027-2
  41. Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966. DOI: 10.1016/j.neuropharm.2020.107966
  42. Contreras-García IJ, Cárdenas-Rodríguez N, Romo-Mancillas A, Bandala C, Zamudio SR, Gómez-Manzo S, et al. Levetiracetam mechanisms of action: From molecules to systems. Pharmaceuticals. 2022;15(4):475. DOI: 10.3390/ph15040475
  43. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861–6. DOI: 10.1073/pnas.0308208101
  44. Trinka E, Höfler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75:1499–521. DOI: 10.1007/s40265-015-0454-2
  45. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61. DOI: 10.5698/1535-7597-16.1.48
  46. Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, et al. Benzodiazepines in the management of seizures and status epilepticus: A review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36(9):951–75. DOI: 10.1007/s40263-022-00940-2
  47. Xue T, Chen S, Bai Y, Han C, Yang A, Zhang J. Neuromodulation in drug-resistant epilepsy: A review of current knowledge. Acta Neurol Scand. 2022;146(6):786–97. DOI: 10.1111/ane.13696
  48. Gouveia FV, Warsi NM, Suresh H, Matin R, Ibrahim GM. Neurostimulation treatments for epilepsy: Deep brain stimulation, responsive neurostimulation and vagus nerve stimulation. Neurotherapeutics. 2024;21(3):e00308. DOI: 10.1016/j.neurot.2023.e00308
  49. Culler GW, Jobst BC. Surgical treatments for epilepsy. Continuum. 2022;28(2):536–58. DOI: 10.1212/CON.0000000000001106
  50. Jiang A, Liu W, Liu Y, Zhang J. Efficacy of ketogenic diet therapy for pediatric drug-resistant epilepsy with monogenic etiology: A single-arm meta-analysis. Nutr Rev. 2025;83(11):2104–22. DOI: 10.1093/nutrit/nuaf140
  51. Borowicz-Reutt K, Czernia J, Krawczyk M. Genetic background of epilepsy and antiepileptic treatments. Int J Mol Sci. 2023;24(22):16280. DOI: 10.3390/ijms242216280
  52. Shaimardanova AA, Chulpanova DS, Mullagulova AI, Afawi Z, Gamirova RG, Solovyeva VV, et al. Gene and cell therapy for epilepsy: A mini review. Front Mol Neurosci. 2022;15:868531. DOI: 10.3389/fnmol.2022.868531
  53. International League Against Epilepsy. ILAE clinical practice guidelines [Internet]. [cited 2025 April 17]. Available from: https://www.ilae.org/guidelines
  54. NICE guideline. Epilepsies in children, young people and adults [Internet]. 2022 April 27 [cited 2025 April 17]. Available from: https://www.nice.org.uk/guidance/ng217